A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.

Trial Details

NCT ID
NCT06905197
Phase
PHASE1
Sponsor
Dizal Pharmaceuticals
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • DZD6008
  • Sunvozertinib
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597
  • Fairfax, Virginia, United States|38.84622,-77.30637
  • Blacktown, New South Wales, Australia|-33.76667,150.91667
  • Camperdown, New South Wales, Australia|-33.88965,151.17642

Key Eligibility Criteria

  • Patients must be able to provide documented informed consent.
  • Aged ≥ 18 years.
  • Histologically or cytologically confirmed diagnosis of NSCLC, locally advanced or metastatic, not suitable for curative therapy.
  • Documentation of EGFR mutations from a local CLIA-certified laboratory (or equivalent). For Part A monotherapy cohorts and all cohorts of Part B, E…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →